Merck & Co.
AWARDS
NEWS
Merck’s Keytruda won FDA approval for the treatment of patients with high-risk, early-stage triple-negative breast cancer. The approval marked the 30th for Keytruda.
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
Merck’s former chief executive officer and current executive chairman, Kenneth Frazier, has stepped down from his post at the pharmaceutical company to join venture capital firm General Catalyst as its newest chairman of health assurance initiatives.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.
JOBS
IN THE PRESS